Arades Phase I/II

• Research type

  Research Study

• Full title

  Safety and Pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer: open, non-randomised, uncontrolled, multicentre, multiple dose escalation study

• IRAS ID

  69475

• Contact name

  Nicholas James

• Sponsor organisation

  Orion Corporation Orion Pharma

• Eudract number

  2010-022802-41

• ISRCTN Number

  N/A

• Research summary

  This study investigates a new treatment for prostate cancer. ODM-201 is a new product and will be administered to human for the first time in this study. The main purpose of this study is to find a dose of the study drug that's efficient and safe in the treatment of prostate cancer.

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  10/H1208/80

• Date of REC Opinion

  25 Feb 2011

• REC opinion

  Further Information Favourable Opinion